Analysis of three studies looks at the role of octagam® for chronic inflammatory demyelinating polyneuropathy patients

Written by Wietek S

Our partner journal, Neurodegenerative Disease Management, recently published the article, ‘Octagam® for chronic inflammatory demyelinating polyneuropathy: results from three observational studies’, presenting data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving octagam® 5% or 10% for chronic inflammatory demyelinating polyneuropathy (CIDP). Find out more in our summary below from the journal’s Commissioning Editor, Laura Dormer, or read the full article for free here.  Editor’s summary Chronic inflammatory demyelinating polyneuropathy (CIDP) is an illness that affects between 1 and 9 people per 100,000. It is believed to be caused by the body’s own...

To view the full article, please register now for access

It's completely free